Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
Andreas Papapetropoulos, Stavros Topouzis, S P H Alexander, Miriam M. Cortese‐Krott, D Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri, Hemal H. Patel, Rainer Schulz, Barbara Stefañska, Gary J. Stephens, Mauro Martins Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy
Abstract
In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as "first-in-class" (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong. The 2023 novel drug list also demonstrates an unabated emphasis on polypeptides (recombinant proteins and antibodies), Advanced Therapy Medicinal Products (gene and cell therapies) and RNA therapeutics, including the first-ever approval of a CRISPR-Cas9-based gene-editing cell therapy.